Dexcom, a glucose monitoring company, reported third-quarter earnings that exceeded sales estimates, generating revenue of $994.20 million, which represents a 1.97% year-over-year increase and beats expectations by $3.49 million. The company's earnings per share (EPS) stood at $0.45, a decline of 10% year-over-year, but still surpassed analyst forecasts by $0.02. Despite these positive results, Dexcom's stock experienced a pre-market decline of 3.6%. The company also announced a transition in its executive leadership, which may have contributed to the stock's downward movement. In related news, ResMed, a manufacturer of sleep apnea devices, reported quarterly profits that exceeded Wall Street estimates, driven by strong demand for its products. ResMed's performance has been buoyed by increasing interest in wearables that monitor sleep, which may positively impact its future sales.